DDInter1744 DDInter1376
Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, side effect profiles, and compliance with [anastrozole]. Tamoxifen was granted FDA approval on 30 December 1977.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Tamoxifen {u} (Compound) resembles {v} (Compound) Methadyl Acetate
Tamoxifen {u} may lead to a major life threatening interaction when taken with {v} Dextropropoxyphene
Tamoxifen {u} (Compound) resembles {v} (Compound) Naftifine
Tamoxifen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Loperamide
Tamoxifen {u} may lead to a major life threatening interaction when taken with {v} Diphenhydramine
Tamoxifen {u} (Compound) treats {v} (Disease) breast cancer
Tamoxifen {u} (Compound) binds {v} (Gene) CYP2E1
Tamoxifen {u} (Compound) upregulates {v} (Gene) SC5D
Tamoxifen {u} (Compound) downregulates {v} (Gene) CCNB2
Tamoxifen {u} (Compound) causes {v} (Side Effect) Thirst
Tamoxifen (Compound) resembles Methadyl Acetate (Compound)
Tamoxifen may lead to a major life threatening interaction when taken with Dextropropoxyphene
Tamoxifen (Compound) resembles Naftifine (Compound)
Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Loperamide
Tamoxifen may lead to a major life threatening interaction when taken with Diphenhydramine
Tamoxifen (Compound) treats breast cancer (Disease)
Tamoxifen (Compound) binds CYP2E1 (Gene)
Tamoxifen (Compound) upregulates SC5D (Gene)
Tamoxifen (Compound) downregulates CCNB2 (Gene)
Tamoxifen (Compound) causes Thirst (Side Effect)